Name: CJC-1295 without DAC- 10mg
SKU: 091-1
Availability: InStock

CJC-1295 without DAC- 10mg

As Low as: $54.30 /per vial

CJC 1295 without DAC, often referred to as Mod GRF 1-29 (Modified Growth Hormone-Releasing Factor (1-29)), is a synthetic analogue of the first 29 amino acids of human growth hormone-releasing hormone (GHRH). Unlike its counterpart with DAC, this peptide is designed for a much shorter duration of action.

$90.00 – $5,430.00

Submit Request

SKU: 091-1 Category:Lyophilized

Description

Quick Facts

CJC 1295 without DAC acts by specifically binding to the GHRH receptors on the somatotroph cells in the anterior pituitary gland. Upon binding, it stimulates the synthesis and secretion of endogenous growth hormone (GH) in a more physiological, pulsatile pattern, closely mimicking the body’s natural release of GH. Due to its short half-life (typically around 30 minutes), its effect is acute and intense, leading to a surge in GH levels that quickly subsides. This rapid on-and-off action allows researchers to study the acute effects of GH pulsatility without prolonged systemic exposure, often used in conjunction with other growth hormone secretagogues to achieve a synergistic effect.

Pulsatile Growth Hormone Release Studies: Ideal for investigations requiring acute, precisely timed stimulation of growth hormone secretion, allowing for detailed study of its immediate physiological impacts.
Synergistic Peptide Research: Often combined with GH Secretagogues (GHS) like Ipamorelin or GHRP-2 in research protocols to explore synergistic effects on GH release and downstream anabolic pathways.
Acute Metabolic Studies: Useful for short-term studies focusing on the acute effects of GH spikes on metabolism, fat oxidation, and glucose regulation.
Endocrine System Dynamics: Employed to understand the dynamic interactions within the hypothalamic-pituitary-somatotropic axis and how specific, brief signals influence overall hormone regulation.
Tissue-Specific Responses: Research into how rapid, transient increases in GH might impact specific tissues or cellular processes.

Why Choose Peptide Chains for CJC 1295 without DAC?

Peptide Chains provides high-purity CJC 1295 without DAC in bulk API quantities, perfectly suited for detailed and controlled scientific experimentation. Our product is supplied in a stable, lyophilized form, ensuring maximal integrity and ease of reconstitution for your precise research needs. We uphold stringent quality control standards, guaranteeing the consistent purity and potency vital for reproducible results in studies focused on acute growth hormone modulation, metabolic dynamics, and synergistic peptide interactions.

Additional information

Weight	0.02 lbs
Dimensions	10 × 15 × 10 in
Vial Quantity	Order a Sample, 10, 20, 50, 100

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog

Abstract

In vivo bioconjugation to the free thiol on Cys34 of serum albumin by a strategically placed reactive group on a bioactive peptide is a useful tool to extend plasma half-life. Three maleimido derivates of human GH-releasing factor (hGRF)(1-29) were synthesized and bioconjugated to human serum albumin ex vivo. All three human serum albumin conjugates showed enhanced in vitro stability against dipeptidylpeptidase-IV and were bioactive in a GH secretion assay in cultured rat anterior pituitary cells. When the maleimido derivatives were individually administered sc to normal male Sprague Dawley rats, an acute secretion of GH was measured in plasma. The best compound, CJC-1295, showed a 4-fold increase in GH area under the curve over a 2-h period compared with hGRF(1-29). CJC-1295, a tetrasubstituted form of hGRF(1-29) with an added N epsilon-3-maleimidopropionamide derivative of lysine at the C terminus, was selected for further pharmacokinetic evaluation, where it was found to be present in plasma beyond 72 h. A Western blot analysis of the plasma of a rat injected with CJC-1295 showed the presence of a CJC-1295 immunoreactive species on the band corresponding to serum albumin, appearing after 15 min and remaining in circulation beyond 24 h. These results led to the identification of CJC-1295 as a stable and active hGRF(1-29) analog with an extended plasma half-life.

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse

Although the majority of children with isolated growth hormone (GH) deficiency have a good growth response to GH-releasing hormone (GHRH), the use of this therapeutic agent is limited by its very short half-life. Indeed, we have shown that, in mice with GHRH gene ablation (GHRH knockout; GHRHKO), even twice-daily injections of a GHRH analog are unable to normalize growth. CJC-1295 is a synthetic GHRH analog that selectively and covalently binds to endogenous albumin after injection, thereby extending its half-life and duration of action. We report the effects of CJC-1295 administration in GHRHKO animals. Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h. Placebo-treated GHRHKO mice and mice heterozygous for the GHRHKO allele served as controls. GHRHKO animals receiving daily doses of CJC-1295 exhibited normal body weight and length. Mice treated every 48 and 72 h reached higher body weight and length than placebo-treated animals, without full growth normalization. Femur and tibia length remained normal in animals treated every 24 and 48 h. Relative lean mass and subcutaneous fat mass were normal in all treated groups. CJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images. These findings demonstrate that treatment with once-daily administration of CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice. The same dose is less effective when administered every 48 or 72 h.